{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:46:35Z","timestamp":1788281195397,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Varian Industries"},{"DOI":"10.13039\/100007210","name":"Varian Medical Systems Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Elekta AB"},{"name":"Accuray Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.euf.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T07:45:28Z","timestamp":1561448728000},"page":"958-969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"5","author":[{"given":"Rohann J.M.","family":"Correa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Ponsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Swaminath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin S.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Muacevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Staehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2019.06.002_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0010","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.eururo.2011.07.064","article-title":"A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis","volume":"60","author":"Sun","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.eururo.2013.03.034","article-title":"Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management","volume":"65","author":"Sun","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2018.03.011","article-title":"Active surveillance for localized renal masses: tumor growth, delayed intervention rates, and &5-yr clinical outcomes","volume":"74","author":"McIntosh","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2018.06.003","article-title":"The probability of aggressive versus indolent histology based on renal tumor size: implications for surveillance and treatment","volume":"74","author":"Bhindi","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0030","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.euf.2017.04.004","article-title":"Active surveillance for small renal masses: when less is more","volume":"2","author":"Ristau","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2019.06.002_bib0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2016.08.039","article-title":"Cryoablation versus partial nephrectomy for clinical T1b renal tumors: a matched group comparative analysis","volume":"71","author":"Caputo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2012.08.062","article-title":"Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma","volume":"63","author":"Psutka","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0033-1363842","article-title":"Percutaneous ablation for small renal masses-complications","volume":"31","author":"Kurup","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.euf.2019.06.002_bib0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2006.03.021","article-title":"Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model","volume":"50","author":"Walsh","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0060","doi-asserted-by":"crossref","first-page":"E737","DOI":"10.1111\/j.1464-410X.2012.11550.x","article-title":"A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma","volume":"110","author":"Siva","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2019.06.002_bib0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.euf.2019.06.002_bib0070","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/S0360-3016(03)01136-2","article-title":"Stereotactic extra-cranial radiosurgery for renal cell carcinoma","volume":"57","author":"Qian","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2019.06.002_bib0075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/01.coc.0000145289.57705.07","article-title":"Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma","volume":"27","author":"Beitler","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","article-title":"Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma","volume":"77","author":"Wersall","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0085","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.ijrobp.2006.07.656","article-title":"2249: Hypo-fractionated stereotactic extra-cranial radiosurgery (HFSR) for primary and metastatic renal cell carcinoma","volume":"66","author":"Gilson","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2019.06.002_bib0090","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0095","first-page":"e6","article-title":"The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT)","volume":"3","author":"Teh","year":"2007","journal-title":"Biomed Imaging Interv J"},{"key":"10.1016\/j.euf.2019.06.002_bib0100","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/02841860802123196","article-title":"Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney","volume":"47","author":"Svedman","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0105","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0167-8140(12)70383-3","article-title":"Oc-0044 Efficacy of stereotactic body radiation therapy for primary renal cell carcinoma","volume":"103","author":"Wurzer","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0110","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1016\/S0167-8140(15)33036-X","article-title":"PO-0730: Stereotactic ablative radiotherapy (SABR) of primary and metastatic renal lesions for patients with single kidney","volume":"106","author":"Chebotareva","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0115","first-page":"6944","article-title":"CyberKnife for inoperable renal tumors: Canadian pioneering experience","volume":"20","author":"Nair","year":"2013","journal-title":"Can J Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0120","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ijrobp.2013.06.218","article-title":"A phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma","volume":"87","author":"McBride","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2019.06.002_bib0125","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/ol.2014.2129","article-title":"Novel application of stereotactic ablative radiotherapy using CyberKnife((R)) for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: initial clinical experiences","volume":"8","author":"Lo","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.euf.2019.06.002_bib0130","first-page":"147","article-title":"Stereotactic body radiotherapy for the treatment of renal tumors","volume":"2","author":"Hanzly","year":"2014","journal-title":"Urol Case Rep"},{"key":"10.1016\/j.euf.2019.06.002_bib0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0140","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0145","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.clon.2016.04.002","article-title":"Stereotactic ablative body radiotherapy for primary renal cell carcinoma in non-surgical candidates: initial clinical experience","volume":"28","author":"Chang","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0150","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/COC.0000000000000329","article-title":"Stereotactic ablative radiotherapy (SABR) for large renal tumors: a retrospective case series evaluating clinical outcomes, toxicity, and technical considerations","volume":"41","author":"Correa","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2214\/AJR.14.14099","article-title":"Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors","volume":"206","author":"Sun","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.euf.2019.06.002_bib0160","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1016\/j.clgc.2017.03.012","article-title":"Stereotactic body radiotherapy for large primary renal cell carcinoma","volume":"15","author":"Kaidar-Person","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2019.06.002_bib0165","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2019.06.002_bib0170","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-16-2946","article-title":"A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2019.06.002_bib0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-018-0992-3","article-title":"A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma","volume":"13","author":"Correa","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0180","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.ijrobp.2018.07.360","article-title":"Dose escalation to 60 Gy in 3 fractions with stereotactic body radiation therapy (SBRT) for poor surgical candidates with localized renal cell carcinoma: expansion of a phase I study","volume":"102","author":"Grubb","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2019.06.002_bib0185","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1111\/cas.13727","article-title":"Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma","volume":"109","author":"Kasuya","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.euf.2019.06.002_bib0190","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818822329","article-title":"Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy","volume":"18","author":"Funayama","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.euf.2019.06.002_bib0195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18632\/oncotarget.26539","article-title":"Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma","volume":"10","author":"Kasuya","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2019.06.002_bib0200","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.23896","article-title":"Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis","volume":"113","author":"Kunkle","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2019.06.002_bib0205","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11547-014-0402-3","article-title":"Stereotactic gamma-ray body radiation therapy for asynchronous bilateral renal cell carcinoma","volume":"119","author":"Wang","year":"2014","journal-title":"Radiol Med"},{"key":"10.1016\/j.euf.2019.06.002_bib0210","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.11941116","article-title":"Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis","volume":"12","author":"Patel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.euf.2019.06.002_bib0215","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","article-title":"Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship","volume":"118","author":"Siva","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13014-014-0253-z","article-title":"Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT\/CT","volume":"9","author":"Jackson","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0225","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/bjs.9811","article-title":"Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer","volume":"102","author":"Pettersson","year":"2015","journal-title":"Br J Surg"},{"key":"10.1016\/j.euf.2019.06.002_bib0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1748-717X-9-39","article-title":"Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review","volume":"9","author":"Musio","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0235","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2019.06.002_bib0240","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamaoncol.2018.6993","article-title":"Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: a phase 2 clinical trial","volume":"5","author":"Palma","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0245","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0090-4295(03)00505-3","article-title":"Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy","volume":"62","author":"Reed","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.euf.2019.06.002_bib0250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0360-3016(96)00390-2","article-title":"Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer","volume":"37","author":"Prestidge","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 2","key":"10.1016\/j.euf.2019.06.002_bib0255","first-page":"S2","article-title":"Radiation therapy failure in prostate cancer patients: risk factors and methods of detection","volume":"4","author":"Brawer","year":"2002","journal-title":"Rev Urol"},{"key":"10.1016\/j.euf.2019.06.002_bib0260","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0265","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","article-title":"Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes","volume":"107","author":"Loblaw","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202387","article-title":"Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma","volume":"13","author":"Reynolds","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2019.06.002_bib0275","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/1754-9485.12590","article-title":"Utility of (68) Ga prostate specific membrane antigen\u2014positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma","volume":"61","author":"Siva","year":"2017","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.euf.2019.06.002_bib0280","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/15384047.2015.1026506","article-title":"Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus","volume":"16","author":"Hannan","year":"2015","journal-title":"Cancer Biol Ther"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919301579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919301579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:49:21Z","timestamp":1762498161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456919301579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2405456919301579"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2019.06.002","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}